
Nectin Therapeutics reports promising Phase 1 data for NTX1088
At the 2026 American Society of Clinical Oncology annual meeting in Chicago, Jerusalem-based Nectin Therapeutics presented Phase 1a/1b results for its lead antibody candidate, NTX1088. The study evaluated the drug in combination with pembrolizumab, showing early signs of anti-tumor activity in patients with heavily pretreated, advanced solid tumors.


























